ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Los Angeles, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Los Angeles, CA, USA:

Locations recently updated

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are be...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Radiation: External-beam radiotherapy (XRT)
Biological: SIRPant-M

Phase 1

SIRPant Immunotherapeutics

Duarte, California, United States and 2 other locations

Locations recently updated

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Los Angeles, California, United States and 66 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Los Angeles, California, United States and 89 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

West Covina, California, United States and 186 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Downey, California, United States and 31 other locations

in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections.All par...

Active, not recruiting
Classical Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biological: GEN3017

Phase 1, Phase 2

Genmab
Genmab

Duarte, California, United States and 5 other locations

1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non...

Enrolling
Non Hodgkin Lymphoma
Drug: IPH6501

Phase 1, Phase 2

Innate Pharma

Los Angeles, California, United States and 11 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Los Angeles, California, United States and 34 other locations

to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...

Enrolling
B-cell Non-Hodgkins Lymphoma (B-NHL)
Drug: REGN5837
Drug: Odronextamab

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Duarte, California, United States and 17 other locations

patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...

Active, not recruiting
Non-Hodgkin's Lymphoma
Small Lymphocytic Lymphoma
Drug: CG-806

Phase 1

Aptose Biosciences

Los Angeles, California, United States and 29 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems